Similar fruits can grow in the most disparate soils. So it would seem when one considers the origins of Keytruda and Opdivo, the twin shining stars in the modern immuno-oncology firmament, owned by Merck and Co and Bristol-Myers Squibb, respectively.
Similar fruits can grow in the most disparate soils. So it would seem when one considers the origins of Keytruda and Opdivo, the twin shining stars in the modern immuno-oncology firmament, owned by Merck and Co and Bristol-Myers Squibb, respectively.
It is interesting to recall that Merck & Co's immuno-oncology breakthrough actually came from Dutch firm Organon, reaching its current owner after
The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).
Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.
Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.
Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.
Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.
The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.
Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.
